Application note: Western blot & IP assay to verify antibody specificity
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
List view / Grid view
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
Researchers have discovered a cross-reactive coronavirus antibody that could aid in the development of a broad-acting vaccine or treatment.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
Researchers have shown that inhalable nanobodies at ultra-low doses can effectively neutralise SARS-CoV-2 in hamsters.
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
Researchers have developed a technique to synthetically produce DNA oligonucleotides that avoids the degradation of phosphoramidites.
A team has characterised a key part of the peptide synthesis process, showing that only the main building block needs to be changed for re-engineering.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.